[{"id":"4706d16d-ce42-4f66-bf31-03fdd9664763","acronym":"CENDIFOX","url":"https://clinicaltrials.gov/study/NCT05121038","created_at":"2021-11-16T13:54:02.602Z","updated_at":"2025-02-25T16:26:46.910Z","phase":"Phase 1/2","brief_title":"CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab","source_id_and_acronym":"NCT05121038 - CENDIFOX","lead_sponsor":"Anup Kasi","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-12-17"},{"id":"a3c3cc0b-d4f9-4e88-af36-4047a3701ec7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03517176","created_at":"2021-01-18T17:18:43.593Z","updated_at":"2024-07-02T16:36:01.739Z","phase":"Phase 1","brief_title":"CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT03517176","lead_sponsor":"Lisata Therapeutics, Inc.","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • certepetide (LSTA1)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 07/31/2018","start_date":" 07/31/2018","primary_txt":" Primary completion: 06/19/2020","primary_completion_date":" 06/19/2020","study_txt":" Completion: 06/19/2020","study_completion_date":" 06/19/2020","last_update_posted":"2022-10-27"}]